Zura Bio price target raised to $21 from $16 at Oppenheimer

Oppenheimer raised the firm’s price target on Zura Bio to $21 from $16 and keeps an Outperform rating on the shares. Zura reported Q1 financial results and provided an update on their development plans for lead candidate tibulizumab across key indications, the analyst tells investors in a research note. Ending cash of $89.8M should support the company through 2027 based on current plans, the firm says.